HUTCHMED (HCM) NDA for fanregratinib gets China priority review status

Rhea-AI Filing Summary

HUTCHMED (CHINA) LIMITED filed a Form 6-K to furnish two exhibits. One is an announcement related to a blocklisting six monthly return, which is a routine administrative update. The other is a press release stating that an NDA in China for fanregratinib in second-line intrahepatic cholangiocarcinoma has been accepted with priority review status, signaling a notable regulatory milestone for this cancer therapy candidate.

Positive

• NDA acceptance with priority review in China for fanregratinib in second-line intrahepatic cholangiocarcinoma represents a significant regulatory milestone that, if successful, could support future commercialization of this oncology therapy candidate.

Negative

• None.

Insights

Biopharma regulatory analyst

NDA priority review in China marks a meaningful regulatory step for HUTCHMED.

The company reports that an NDA in China for fanregratinib in second-line intrahepatic cholangiocarcinoma has been accepted with priority review status. NDA acceptance is a key gate for commercialization, and priority review typically reflects the perceived clinical need.

The impact ultimately depends on regulatory evaluation outcomes and any conditions that may arise, which are not detailed here. Future company communications may clarify timelines, review progress, and any subsequent commercialization steps if the NDA is approved.

Form 6-K: How Foreign Companies Report to the SEC →

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of December 2025

​

Commission File Number: 001-37710

​

​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​

​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.	​ ​ ​	Description
​	​	​
Exhibit 99.1	​	Announcement relating to blocklisting six monthly return ​
Exhibit 99.2	​	Press release relating to NDA Acceptance in China with priority review status for fanregratinib in second-line intrahepatic cholangiocarcinoma
​	​	​
​	​	​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​	HUTCHMED (CHINA) LIMITED
​	​	​
​	​	​
​	By:	/s/ Johnny Cheng
​	Name:	Johnny Cheng
​	Title:	Chief Financial Officer

​

​

Date: December 29, 2025

3

FAQ

What did HUTCHMED (HCM) report in its December 2025 Form 6-K?

HUTCHMED filed a Form 6-K furnishing two exhibits: a routine announcement on a blocklisting six monthly return and a press release stating that an NDA in China for fanregratinib in second-line intrahepatic cholangiocarcinoma was accepted with priority review status.

What is the key regulatory update disclosed by HUTCHMED (HCM)?

The key update is that an NDA in China for fanregratinib in second-line intrahepatic cholangiocarcinoma has been accepted with priority review status, indicating regulators will review the application on an expedited basis due to its potential importance for patients.

Which drug candidate is mentioned in HUTCHMED’s (HCM) Form 6-K?

The Form 6-K references fanregratinib, a therapy candidate for second-line intrahepatic cholangiocarcinoma. The company reports that its NDA for this indication in China has been accepted with priority review, highlighting progress in its oncology development pipeline.

What cancer indication is targeted by fanregratinib in HUTCHMED’s (HCM) filing?

Fanregratinib is targeted for second-line intrahepatic cholangiocarcinoma. The filing notes that an NDA in China for this indication has been accepted with priority review, underscoring a focus on treating a specific form of bile duct cancer in a later-line setting.

Does HUTCHMED’s (HCM) Form 6-K include any routine administrative updates?

Yes. One exhibit is an announcement relating to a blocklisting six monthly return, which is an administrative update regarding listed securities. This appears alongside the more notable exhibit on NDA acceptance with priority review for fanregratinib in China.

Who signed HUTCHMED’s (HCM) December 2025 Form 6-K?

The Form 6-K was signed on behalf of HUTCHMED (CHINA) LIMITED by Johnny Cheng, who is identified in the document as the company’s Chief Financial Officer, confirming the filing’s authorization by senior management.